Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: A case report

被引：52

作者：

Claudia Colomba

Raffaella Rubino

Lucia Siracusa

Francesco Lalicata

Marcello Trizzino

Lucina Titone

Manlio Tolomeo

机构：

[1] Dipartimento di Scienze per la Promozione della Salute, Sezione di Malattie Infettive, Università di Palermo, 129-90127, Palermo, Via del Vespro

来源：

BMC Research Notes | / 5卷 / 1期

关键词：

Myelofibrosis; Ruxolitinib; Tuberculosis;

D O I：

10.1186/1756-0500-5-552

中图分类号：

学科分类号：

摘要：

Background: Primary myelofibrosis is a myeloproliferative disorder characterized by bone marrow fibrosis, abnormal cytokine expression, splenomegaly and anemia. The activation of JAK2 and the increased levels of circulating proinflammatory cytokines seem to play an important role in the pathogenesis of myelofibrosis. Novel therapeutic agents targeting JAKs have been developed for the treatment of myeloproliferative disorders. Ruxolitinib (INCB018424) is the most recent among them. Case presentation. To our knowledge, there is no evidence from clinical trials of an increased risk of tuberculosis during treatment with JAK inhibitors. Here we describe the first case of tuberculosis in a patient treated with Ruxolitinib, a male with a 12-year history of chronic idiopathic myelofibrosis admitted to our Institute because of fever, night sweats, weight loss and an enlarging mass in the left inguinal area for two months. Conclusion: Treatment with Ruxolitinib may have triggered the reactivation of latent tuberculosis because of an inhibition of Th1 response. Our case highlights the importance of an accurate screening for latent tuberculosis before starting an anti-JAK 2 treatment. © 2012 Colomba et al.; licensee BioMed Central Ltd.

引用

共 8 条

[1]

Baxter E.J., Scott L.M., Campbell P.J., Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, Lancet, 365, 9464, pp. 1054-1061, (2005)

[2]

Kralovics R., Passamonti F., Buser A.S., A gain-of-function mutation of JAK2 in myeloproliferative disorders, N Engl J Med, 352, 17, pp. 1779-1790, (2005)

[3]

Tefferi A., Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management, Am J Hematol, 86, 12, pp. 1017-1026, (2011)

[4]

Deisseroth A.B., Kaminskas E., Grillo J., Chen W., Saber H., Lu H., Rothmann M.D., Brar S.S., Wang J., Garnett C., Bullock J., Burke L., Rahman A., Sridhara R., Farrell A., US Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with intermediate and high Risk Myelofibrosis, Clin Cancer Res, 15, 12, pp. 3212-3217, (2012)

[5]

Harrison C., Kiladjian J.J., Al-Ali H.K., Gisslinger H., Waltzman R., Stalbovskaya V., McQuitty M., Hunter D.S., Levy R., Knoops L., Cervantes F., Vannucchi A.M., Barbui T., Barosi G., JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis, N Engl J Med, 366, 9, pp. 787-798, (2012)

[6]

Verstovsek S., Kantarjian H., Mesa R.A., Pardanani A.D., Cortes-Franco J., Thomas D.A., Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis, N Engl J Med, 363, 12, pp. 1117-1127, (2010)

[7]

Ostojic A., Vrhovac R., Verstovsek S., Ruxolitinib for the treatment of myelofibrosis: Its clinical potential, Ther Clin Risk Manag, 8, pp. 95-103, (2012)

[8]

Boehm U., Klamp T., Groot M., Howard J.C., Cellular responses to interferon-gamma, Annu Rev Immunol, 15, pp. 749-795, (1997)

← 1 →